Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Sep;131(3):307-16.
doi: 10.1016/j.otohns.2004.02.018.

Sclerotherapy for congenital lesions in the head and neck

Kwang Hyun Kim  1 , Myung-Whun Sung, Jong-Lyel Roh, Moon Hee Han
Affiliations

Sclerotherapy for congenital lesions in the head and neck

Kwang Hyun Kim et al. Otolaryngol Head Neck Surg. 2004 Sep.

Abstract

Objectives: This study retrospectively reviews the results of sclerotherapy using several sclerosants for congenital lesions of the head and neck.

Methods and patients: Between May 1990 and May 2002, patients with lymphatic malformations were treated by sclerotherapy; 10 with bleomycin, and 25 with OK-432. OK-432 sclerotherapy was also applied in 9 patients with plunging ranula and in 1 patient with branchial anomaly. Percutaneous sclerotherapy with ethanolamine oleate was used in 29 patients with venous malformations, and 28 patients with pyriform sinus fistula were treated by trichloroacetic acid chemocauterization.

Results: Overall, two thirds of patients with these lesions showed marked to complete response. One case of mortality occurred in the bleomycin sclerotherapy group. However, no major complications by other sclerosants were found. In lymphatic malformations, history of excision before sclerotherapy was a poor prognostic factor.

Conclusion: Sclerotherapy using these sclerosants is a safe and effective primary treatment for congenital lesions in the head and neck.

PubMed Disclaimer

Publication types